Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program

blonca9
Dec 12, 2024
1 min read

CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and manufacturing protein-based medicines. He then walks us through the company’s development plans.

Recent Posts

See All

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight